REG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Last Day of Dealings on AIM

MaxCyteAnnouncement

25/06/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250625:nRSY2475Oa&default-theme=true

RNS Number : 2475O  MaxCyte, Inc.  25 June 2025

 

 

MaxCyte Inc.

("MaxCyte" or the "Company")

Last Day of Dealings on AIM

 

ROCKVILLE, Md., LONDON, UK., 25 June, 2025 MaxCyte, Inc. (Nasdaq: MXCT; LSE:
MXCT), a leading, cell-engineering focused company providing enabling platform
technologies to advance the discovery, development and commercialization of
next-generation cell therapeutics today provides a further update with regards
to the cancellation of admission of the Company's common stock ("Common
Stock") to trading on AIM (the "Cancellation"), as approved by shareholders at
the Annual General Meeting held on 18 June 2025.

Shareholders are reminded that the last day of dealings in the Company's
Common Stock on AIM will be 25 June 2025 and that the cancellation of their
admission to trading on AIM will take place at 7:00 a.m. (UK time) on 26 June
2025.

Following the delisting, there will be no public market in the United Kingdom
on which the Common Stock can be traded, however the Company will retain
its U.S. listing of Common Stock on the Nasdaq Global Select Market
("Nasdaq") under ticker symbol MXCT.

Further information regarding the delisting can be found at:
https://investors.maxcyte.com/static-files/529f4a8b-c6e9-4db6-bfc1-6a2da9f0252a
(https://investors.maxcyte.com/static-files/529f4a8b-c6e9-4db6-bfc1-6a2da9f0252a)
.

For further information, please contact:

 

   MaxCyte Contacts:

   US IR Adviser                                 +1 415-937-5400

   Gilmartin Group                               ir@maxcyte.com

   David Deuchler, CFA

   Nominated Adviser and Joint Corporate Broker

   Panmure Liberum                               +44 (0)20 7886 2500

   Emma Earl / Mark Rogers

   Corporate Broking

   Rupert Dearden

   UK IR Adviser                                 +44 (0)203 709 5700

   ICR Healthcare                                maxcyte@icrhealthcare.com

   Mary-Jane Elliott

   Chris Welsh

 

About MaxCyte

At MaxCyte(®), we are committed to building better cells together. As a
leading cell-engineering company, we are driving the discovery, development
and commercialization of next-generation cell therapies. Our best-in-class
Flow Electroporation(®) technology and SeQure DX™ gene editing risk
assessment services enable precise, efficient and scalable cell engineering.
Supported by expert scientific, technical and regulatory guidance, our
platform empowers researchers from around the world to engineer diverse cell
types and payloads, accelerating the development of safe and effective
treatments for human health. For more than 25 years, we've been advancing cell
engineering, shaping the future of medicine. Learn more at maxcyte.com
(https://www.globenewswire.com/Tracker?data=f7MZAm2OsUduwxl6CYAmgoKCIwuYkIpwN743nOeFpfmoPR6FlUlBKF0ZGi05jNB7Quo4OaRNy6-wB8Bmz3t0g5An8O856Cvhpo2-lTGLir6xz5Qv05BrIhxU0P2cv2fVS9v8mjQflKTdySxyK_ACrj9zVEEiPAng9ac3AXqjttnVG9TQ4JjcpvQLuCho8U-APV7NFdO5-8tE3CwW582nuGsj7IO01TIFSuOfQej1dcxGF-phV0fpqoojJi5rpGzF2BaQT5X8ickxDTxEGeHb-99GJ96MnnY1LZZUGHl07FPGbt-if015P2rKdy2llQRgukpvX_wiHw44KbiBVjjg0Oewa1gsjlHjSvP7piyIblZ8fP1ny_7F8FOg79eqI5-8)
 and follow us on X
(https://www.globenewswire.com/Tracker?data=rjuRjaZHpEXzNljmpsgvNWQpu2NKxGiErlhs4csnoJ4LVC_R6EOOAlsgidOHGozxdXLhsj6Z1W7nLswWB1Z1MmaG1tbqOIdTaSS3_ARw8gLjlJb2Ow5_pMyYhwMlDlNkRe1hYqiW2TKuUwL1oIEoLfGNB7BjvVSN8irQpxq-oJypHQ6IDcBNPpVNkYIy4YdLyz_UeBiyw8tUFVJ0iQNFJsGRGIPFfIy9qf0LyAmEgaLi73dMaItKZAvb41MRnVwRl8xUzRWW_EQkCTK7qgWmjatusSKXx4VkYn80WX4JUEyK13JFiGqTv2uYxmHROZvcsKAONecH1cg7kR4Eg5m86CyfRGWfa6eSPCWzVlJznDfRbk2DMo8pCyIEZ49-dSjf)
 and LinkedIn
(https://www.globenewswire.com/Tracker?data=vcNmZbomBnBvgZ7X0zu3oYyECP-sTjHMbgigqrWax_SW6J6f63Vz3B0S2bQmloni5Rg1Twb9HS-4XqRKgZ3NtMDRpnxDtPc-_C2CO08P-BBdyyGetjYjwPWjlrlz4jE2hyvKC0j99b9zsj6n8eWbTw==)
.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFIMFTMTBTBLA